Growth Metrics

Emergent BioSolutions (EBS) Asset Writedowns and Impairment (2016 - 2025)

Emergent BioSolutions (EBS) has 10 years of Asset Writedowns and Impairment data on record, last reported at $27.2 million in Q2 2024.

  • For Q2 2024, Asset Writedowns and Impairment fell 91.13% year-over-year to $27.2 million; the TTM value through Sep 2025 reached $27.2 million, changed N/A, while the annual FY2025 figure was $12.2 million, 55.15% down from the prior year.
  • Asset Writedowns and Impairment reached $27.2 million in Q2 2024 per EBS's latest filing, down from $306.7 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $306.7 million in Q2 2023 and bottomed at $27.2 million in Q2 2024.